TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)

Sponsor
Krankenhaus Barmherzige Schwestern Linz (Other)
Overall Status
Completed
CT.gov ID
NCT04400578
Collaborator
Medical University of Vienna (Other)
102
1
1
23.4
4.4

Study Details

Study Description

Brief Summary

Trichloroacetic acid 85% =TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2. The device system is to be used only in accordance with the approved Investigational Plan on subjects, who have given written informed consent.

High remission and regression rates are expected after a single topical treatment with 85% TCA. After a single topical treatment with 85% TCA for CIN 1-2 (Expected 70% or higher; null hypothesis: not higher than 55%). Regression is defined as improvement from high grade lesion (CIN 2) at baseline to low grade lesion (CIN 1) after TCA treatment. Regression from CIN 1 normal squamous epithelium after the TCA treatment is equal to remission and will be counted as a remission in combined analysis. Remission is defined as complete histologic remission of CIN back to normal squamous epithelium after the TCA treatment, i.e., no cervical dysplasia is detectable by histology or cytology after the TCA treatment. Type-specific HPV Clearance is defined as disappearance of the HPV type detected at screening.

Condition or Disease Intervention/Treatment Phase
  • Device: Trichloroacetic acid 85% (TCA)
N/A

Detailed Description

Visit and assessment Schedule:
Visit1 Screening:
  • Informed Consent,

  • Inclusion/Exclusion Criteria,

  • Medical History,

  • Gynecological Examination

  • Cytology

  • HPV Test

  • Colposcopy

  • Biopsy

  • VAS (Visual analog scale)

  • Pregnancy test

Visit 2 Treatment Day with TCA 85%:
  • Colposcopy

  • TCA Treatment

  • VAS

  • Pregnancy test

Visit 3, Control 1, Week 10-14:
  • Cytology

  • HPV Test

  • Colposcopy

  • Biopsy

  • 4-quadrant biopsy

  • ECC

  • Adverse event monitoring If there is no sign of CIN during the colposcopic examination 10-14 weeks a 4-quadrant biopsy and a ECC are performed

Visit 4, Control 2, Week 22-26:
  • Cytology

  • HPV Test

  • Colposcopy

  • Biopsy

  • 4-quadrant biopsy

  • ECC

  • Adverse event monitoring

  • Pregnancy test If there is no sign of CIN during the colposcopic examination 22-26 weeks after the TCA treatment, a 4-quadrant biopsy and a ECC are performed.

Visit 5, EOS , Week 24-30:
  • Results Discussion

Study Design

Study Type:
Interventional
Actual Enrollment :
102 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
TRICIN: Prospective Study on the Efficacy of Single Topical Trichloroacetic Acid (TCA) 85% in the Treatment of Cervical Intraepithelial Neoplasia (CIN 1/2)
Actual Study Start Date :
Feb 7, 2020
Actual Primary Completion Date :
Jan 18, 2022
Actual Study Completion Date :
Jan 18, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: TRICIN

If a patient is eligible local anesthesia with Xylocain 10% with a pump spray for a period of 10 seconds- one time application Procain 2%: local anesthesia with a swab for a period of 10 seconds- one time application Trichloroacetic acid TCA 85% 1-2 ml with soaked swab for max. 2 minutes -one time application

Device: Trichloroacetic acid 85% (TCA)
Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.

Outcome Measures

Primary Outcome Measures

  1. CIN remission rate after treatment with TCA 85% [6 months]

    measured by histologic remission within 6 months

Secondary Outcome Measures

  1. CIN regression rate after treatment with TCA 85% [6 months]

    measured by histologic regression within 6 (improvement of at least one clinical CIN grade) months

  2. Pain scores [6 months]

    measured by Visual Analogue Scale of a single use of TCA 85% in patients with CIN 1/2

  3. Type specific human papillomavirus clearance rate after treatment with TCA 85% [6 months]

    human papillomavirus clearance rate after treatment with TCA 85% with CIN I/CIN // within 6 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Histologically proven CIN 1/2

  • adequate colposcopy (i.e. fully visible transformation zone and margins of any visible lesion)

  • positive HPV test

  • conducted negative pregnancy test

  • women aged 18 to 50 years

  • written informed consent

Exclusion Criteria:
  • Exclusion criteria are a cytologically suspected CIN (Pap IIID, IV)

  • inadequate colposcopy

  • negative or missing biopsy

  • cytology results indicating invasive disease (PAP V)

  • if the cervical lesion recedes into the endocervical canal

  • pregnancy

  • any medical circumstance considered relevant for proper performance of the study, or risks to the patient, at the discretion of the investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern Linz Austria 4010

Sponsors and Collaborators

  • Krankenhaus Barmherzige Schwestern Linz
  • Medical University of Vienna

Investigators

  • Principal Investigator: Lukas Hefler, MD, Krankenhaus Barmherzige Schwestern Linz

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Krankenhaus Barmherzige Schwestern Linz
ClinicalTrials.gov Identifier:
NCT04400578
Other Study ID Numbers:
  • EKS 48/19
First Posted:
May 22, 2020
Last Update Posted:
Apr 7, 2022
Last Verified:
Mar 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022